Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.43 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.43 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.43 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.43 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.43 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.43 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | TYK2 | P29597 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420958 | 0.84 | LMNA (0.42) | KCNH2HTR2ASLC6A4PSEN1PSEN2 | |
| SCHEMBL17553255 | 0.82 | KCNH2 (0.43) | KCNH2HTR2ASLC6A4PSEN1PSEN2 | |
| SCHEMBL31521500 | 0.82 | LMNA (0.50) | KCNH2HTR2ASLC6A4PSEN1PSEN2 | |
| SCHEMBL30142930 | 0.82 | PDE2A (0.47) | KCNH2HTR2ASLC6A4PSEN1PSEN2 | |
| SCHEMBL19115614 | 0.82 | KCNH2 (0.43) | KCNH2HTR2ASLC6A4PSEN1PSEN2 | |
| SCHEMBL23489650 | 0.82 | PDE2A (0.47) | KCNH2HTR2ASLC6A4PSEN1PSEN2 | |
| SCHEMBL16957963 | 0.82 | KCNH2 (0.43) | KCNH2HTR2ASLC6A4PSEN1PSEN2 | |
| SCHEMBL17216071 | 0.82 | PDE2A (0.47) | KCNH2HTR2ASLC6A4PSEN1PSEN2 | |
| SCHEMBL2588946 | 0.82 | PDE2A (0.47) | KCNH2HTR2ASLC6A4PSEN1PSEN2 | |
| SCHEMBL29167805 | 0.82 | LMNA (0.50) | KCNH2HTR2ASLC6A4PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024103400-A1 | POLYCYCLIC COMPOUND AS GPR75 ACTIVATOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 水木未来(北京)科技有限公司 | 2024-05-23 | — | — | WO | disclosed |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230322799-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-10-12 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322799-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNITED STATES GOVERNMENT | 2023-10-12 | — | — | US | disclosed |
| US-20230265110-A1 | Proteasome Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-24 | — | — | US | disclosed |
| WO-2009020448-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20090042836-A1 | e.g. 1-({[(2,3-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; anticarcinogenic, antiproliferative agent | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| US-7442830-B1 | Proteasome inhibitors | MILLENIUM PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| US-20070105890-A1 | Novel condensed imidazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD | 2007-05-10 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
| US-20070082908-A1 | Bicycle pyrazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | KCNH2 4791/4885HTR2A 3529/4885SLC6A4 4135/4885 |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KCNH2 2789/4885HTR2A 2793/4885SLC6A4 4513/4885 |
| US-20230322799-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM2 | KCNH2 249/4885HTR2A 323/4885SLC6A4 457/4885 |
| US-20070105890-A1 | Novel condensed imidazole derivative | DPP4, DPP7, DPP3 | KCNH2 604/4885HTR2A 1167/4885SLC6A4 145/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | KCNH2 2789/4885HTR2A 2793/4885SLC6A4 4513/4885 |
| US-20230265110-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | KCNH2 4243/4885HTR2A 4505/4885SLC6A4 4724/4885 |
| US-20070082908-A1 | Bicycle pyrazole derivative | DPP4, DPP7, DPP3 | KCNH2 806/4885HTR2A 1714/4885SLC6A4 419/4885 |
| US-11912668-B2 | GCN2 and perk kinase inhibitors and methods of use thereof | EIF2AK4, GCN1, MAPKAPK2 | KCNH2 3737/4885HTR2A 3263/4885SLC6A4 3957/4885 |
| US-20090042836-A1 | e.g. 1-({[(2,3-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid; anticarcinogenic, antiproliferative agent | PSMB1, PSMB11, PSMB5 | KCNH2 3697/4885HTR2A 4568/4885SLC6A4 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.